Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis
Jean‐Jacques Kiladjian(Délégation Paris 5), Bruno Cassinat(Inserm), Matthieu Resche‐Rigon(Inserm), Valérie Rolland‐Neyret(Centre Hospitalier Universitaire de Grenoble), Fiorenza Barraco(Hôpital Lyon Sud), Françoise Boyer‐Perrard(Centre Hospitalier Universitaire d'Angers), Sylvie Chevret(Saint Louis University Hospital), Stéphane Giraudier(Inserm), Claude Capron(Hôpital Ambroise-Paré), Juliette Soret‐Dulphy(Inserm)
Cited by 26
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777